SA Oncologist reassures patients after word of counterfeit cancer drugs

BROTHERLY LOVE: Valentine's visit lifts sister's spirits

http://www.ksat.com/news/START-Center-begins-groundbreaking-genome-study/-/478452/8770914/-/6i7o9a/-/index.html

San Antonio's START cancer center takes part in study Pancreatic cancer is the fourth leading cause of death among cancers. But there is new hope for treatment of the disease in some patients.

A San Antonio college student who beat a scary cancer diagnosis is spreading her message of hope.

SAN ANTONIO -- A drug just approved by the FDA less than 2 weeks ago is giving hope to people with advanced stages of melanoma that has spread to other organs. The drug boosts the immune system to fight off the cancer. A San Antonio dermatologist became part of the clinical trials for this new drug when she herself discovered a melanoma that spread to her lymph nodes and lungs.

It is the first spa of its kind to open in San Antonio and South Texas and is one of only a handful of such facilities in the US that is designed entirely ...

MethylGene Inc. (TSX:MYG) today disclosed safety and efficacy clinical data for MGCD265 in two poster presentations at the 22nd EORTC-NCI-AACR Symposium held in Berlin, Germany. Data was presented for the Company’s two-arm trial (Trial 103) in which MGCD265 is administered in combination with either docetaxel or erlotinib in solid tumor patients. MGCD265 is a proprietary oral multi-targeted receptor tyrosine kinase inhibitor.

START Madrid, Spain’s leading Phase I testing center for new anti-cancer drugs, has received an anonymous donation of $279,306 to support its operations.